1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Liaw YF,Leung N,Kao JH,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008update.Hepatol Int,2008,2:263-283.
7Liaw YF.Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.Liver Int,2009,29Suppl 1:100-107.
8Leung N.Recent data on treatment of chronic hepatitis B with nucleos (t) ide analogues.Hepatol Int,2008,2:163 -178.
9Pawlotsky JM,Dusheiko G,Hatzakis A,et al.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice:recommendations for a standardized approach.Gastroenterology,2008,134:405-415.
10Villa E,Lei B,Taliani G,et al.Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients:a pilot study.Antivir Ther,2009,14:1081-1087.
